BioMed Research International
Volume 2015 (2015), Article ID 187384, 8 pages
http://dx.doi.org/10.1155/2015/187384

Review Article

Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers

Radmilo Janković,1,2 Danica Marković,¹ Nenad Savić,¹ and Vesna Dinić¹

¹Center for Anesthesiology and Reanimatology, Clinical Center in Niš, Bulevar Dr. Zorana Djindjića 48, 18000 Niš, Serbia
²Department for Anesthesia and Intensive Care, School of Medicine, University of Niš, Bulevar Dr. Zorana Đinđića 81, 18000 Niš, Serbia

Received 14 June 2015; Revised 3 August 2015; Accepted 17 August 2015

Academic Editor: Mitja Lainscak

Copyright © 2015 Radmilo Janković et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Preoperative assessment of cardiovascular risk is essential when it comes to extensive noncardiac surgery procedures. Therefore, accurate and timely diagnosis of myocyte damage is vital. In modern medical practice it is believed that the so-called “multimarker” approach is the most appropriate and most accurate, but new research points out that there are novel biomarkers which could be used independently. Studies that evaluate miRNA, H-FABP, and MR-PAMP give encouraging results. When it comes to miRNA clinical studies show high statistical significance, especially in the case of acute myocardial infarction (). Statistical significance of was found in acute coronary syndrome, when H-FABP was measured. Biochemical marker MR-PAMP showed statistical significance of in most clinical studies.

1. Introduction

Anesthesiologists are daily in contact with patients who are preparing for noncardiac surgery procedures and who are at increased risk to develop cardiovascular complications in perioperative period. The number of these patients is increasing worldwide [1, 2]. Perioperative risk can be estimated based on the severity of existing heart failure, development of recent myocardial infarction, existence of arrhythmias, presence of aortic stenosis, patient’s age, type of planned surgery, chronic obstructive pulmonary disease, renal function, previous transient ischemic attack, the general condition of the patient, and so forth [3–6]. Postoperative hypertension, arrhythmia, and heart failure usually occur two days after surgery, while the risk of perioperative myocardial infarction persists during five to six postoperative days [3]. In total, less than 1% of patients develop perioperative myocardial infarction; however about two-thirds of these patients die within 30 postoperative days. Therefore, timely preoperative diagnosis of myocyte damage is vital [1]. Until recently Lee score was used to assess perioperative risk; however European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA) have proposed a new and comprehensive way to evaluate perioperative cardiac risk [7, 8]. Significant item of this preoperative evaluation and processing of high-risk patients are biomarkers. We have evaluated potential use of miRNA, H-FABP, and MR-PAMP in everyday clinical practice as well as the characteristics which make them stand out as highly promising novel biomarkers.

2. Biomarkers in Clinical Practice

Biological marker or biomarker can be objectively measured and it is an indicator of biological processes [8]. From the definition, ideal biomarker has the following characteristics: a high presence in the heart tissue, an absence in other tissues, an absence in the serum of healthy individuals, quick release for the purpose of early diagnosis, a long half-life for the purpose of late diagnosis, cost-effectiveness, and positive evaluation in clinical trials [9–11]. The search for an ideal cardiac biomarker lasts for almost a century (Table 1).

Table 1: Brief history of cardiac biomarkers.

Biomarker
Year of first appearance in literature
One of the first significant references when it comes to myocardial injury

H-FABP
1988
[68]

AST
1954
[69]

LDH
1948
[70]

CK
1954
[71]

HBDH
1963
[72]

CK-MB
1962
[73]

CK-MB mass
1986
[74]

Myoglobin
1941
[75]

TnT
1940
[76]

TnI
1987
[77]

miRNA
2009
[37]

PAMP
2002
[78]

In modern medicine practice there are numerous biomarkers, those that point to an obvious pathology of cardiomyocytes and those that provide a strong evidence of comorbidity such as acute renal failure and pneumonia [12]. The following biomarkers are currently used: aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK), hydroxybutyrate dehydrogenase (HBDH), creatine kinase MB isoenzyme (CK-MB), CK-MB mass, myoglobin, carbonic anhydrase, glycogen phosphorylase BB, troponin T (TnT), and troponin I (TnI) [9, 13]. According to the latest recommendations, biomarkers which determine myocardial ischaemia and damage, inflammation, and left ventricular function are used in the perioperative period. The most popular biomarkers in modern practice are cTnI and cTnT due to higher sensitivity and specificity when compared to other biomarkers. Clinical studies have shown that even a small increase in the concentration of cTnT in the perioperative period indicates myocardial damage and worsens postoperative prognosis and outcome. Preoperative determination of BNP and NT-pro-BNP levels indicates the possibility of developing cardiovascular complications after major noncardiovascular surgeries [8, 13–16]. Biomarkers also have a great role in improving the treatment of heart diseases and monitoring of the effectiveness of the therapy [12]. There is the fact that there are no biomarkers which can be interpreted and included in routine work alone but can only indicate the high-risk patients [8].

It is believed that a multimarker approach is the most appropriate and most accurate and that a new set of biomarkers (currently in the trial phase) is much more accurate and that they could even be used independently [12]. The development and definition of new biomarkers will lead to a faster and more accurate diagnosis of myocardial damage [8, 17]. A large number of studies about new potential biomarkers of myocardial damage such as microRNA (mrRNA), fatty acid-binding protein (FABP), and proadrenomedullin (PAMP) are currently conducted (Figure 1).

Figure 1: Biomarkers and their precursors in serum after cell apoptosis and necrosis.

3. The Significance of miRNA as a Biomarker

MicroRNA (miRNA) represents a recently discovered class of endogenous, small, noncoding RNA molecules which regulate the expression of approximately 30% of genes in the human genome and are highly stable in the circulation [2, 18–22]. Basic and clinical studies indicate a great importance of miRNA in the regulation of cellular differentiation, growth, proliferation, and apoptosis [23–25]. Besides miRNA, which are specific for the majority of tissues, there are also miRNAs with a tissue-specific expression and they could be useful in practice [19, 26, 27].

These molecules can be transported between the cells in the form of miRNA bound to RISC, Argonaute 2, and Nucleophosmin 1 proteins as well as in the form of miRNA packed in vesicles. It is considered that a free miRNA molecule can be found in blood as a consequence of the release of the cell contents in plasma due to necrosis [26].

The role of miRNA was first studied in the field of oncology, where they were considered to be both oncogenes and tumor suppressors [2, 28]. Earlier studies indicated a great expression of miRNA in the heart cells; however their role has not been completely known until the beginning of the research in 2005 [2, 19]. Research based on miR-155 has indicated that it has a key role in the development of immune disorders, tumors, cardiovascular diseases, viral infections, and so forth [29]. It has later been shown that miRNA molecules are essential for the proper development of cardiovascular system [26]. Some of the miRNAs expressed in the heart tissue are miR-21, miR-29a, miR-129, miR-210, miR-211, miR-320, miR-423, and let-7c. In a completely healthy heart tissue miR-1, miR-16, miR-27b, miR-30d, miR-126, miR-133, miR-143, miR-208, and let-7 families are highly expressed [21].

An aberrant presence of miR-21 in the blood vessel wall after balloon damage has been proved by using microarray and Northern blot analysis as well as qRT PCR method [30]. Several studies made miRNA target molecules in the therapy of atherosclerosis, postangioplastic restenosis, transplantation arteriopathy, and cerebral and heart ischaemia [30–32]. Cipollone et al. have examined 41 miRNAs and discovered profound differences in the expression of miR-100, miR-127, miR-145, miR-133a, and miR-133b in symptomatic versus asymptomatic plaques [33].

Myocardial hypertrophy represents a great determinant in predicting the mortality and morbidity in cardiovascular diseases [2]. Significant negative effects on the myocardial hypertrophy were obtained by changing the expression of miR-21 by knockdown method, or antisense-mediated depletion method. It can be concluded that miRNA is involved in the process of myocardial hypertrophy and can represent a future target in the therapy of diseases which include myocardial hypertrophy like hypertension, ischaemic heart disease, valvular heart disease, and endocrine diseases [2]. Studies have shown that miR-1, miR-21, miR-133, miR-195, and miR-208 have the most important role in the development of hypertrophy [25].

Lovren et al. have shown that miRNA-145 is highly expressed in the smooth muscle cells of blood vessels and that its overexpression can lead to the development of atherosclerosis [28]. Other miRNAs expressed in the atherosclerosis are miR-126, miR-145, miR-146a, miR-155, and miR-210 [23, 27]. miRNA-145 molecule controls the differentiation of smooth muscle cells and promotes the formation of lesion; miR-126 sends signals about the need to repair endothelium, while miR-155 indicates the presence of proinflammatory macrophages and atherosclerotic lesions [34, 35]. Research about the influence of miRNA on the development of atherosclerosis is a relatively new field so it is considered that the full clinical potential of this molecule in that area is yet to be demonstrated [26, 34].

Patients with arterial coronary disease have decreased levels of miR-126, miR-145, and miR-155 in circulation. Many studies are currently trying to assess the impact of miR-1, miR-133a, miR-133b, miR-208, miR-499, and miR-499-5p on the development of acute myocardial infarction [21]. It has been proved that miR-208b, miR-499, and miR-320a have been significantly elevated in the patients with acute myocardial infarction; however none of them could be used independently in the diagnostics without cTnT or hsTnT [36]. Wang et al. have reported that elevated levels of cardiac-specific miR-208a in plasma may represent a new biomarker for early detection of myocardial damage [37]. Also circulating miR-1, miR-133a, miR-208b, and miR-499 may be useful biomarkers in acute myocardial infarction, but they are not superior to cTnT [38]. However, according to research circulating miR-499 represents a new early biomarker for the identification of perioperative myocardial infarction in cardiac surgery [39].

Atrial fibrillation is associated with reduced levels of miR-1 in atrial tissue and an overexpression of miR-133 and miR-328 [21, 25]. Cardin et al. have concluded that knockdown of the gene miR-21 in atrium suppresses atrial fibrosis and the onset of atrial fibrillation, and therefore miR-21 is an important signaling molecule for the development of this disorder [40]. It is also considered that miR-1 is responsible for the changes in function of many proteins which take over Ca2+, so it is connected with the onset of ventricular fibrillations [21].

It is considered that miRNAs have a significant impact on the development of hypertension, especially through the influence on the renin-angiotensin-aldosterone system. Some of the significant miRNAs for the hypertension onset are miR-181a, miR-663, miR-132, miR-212, miR-143, and miR-145 [21].

The onset of heart failure is connected to miR-122, miR-210, miR-423, miR-5p, miR-499, and miR-622. Research points out to a high specificity of miR-16, miR-27a, miR-101, and miR-150 in predicting the occurrence of left ventricular failure six months after acute myocardial infarction [21]. Circulating miR-423 and miR-5p are considered potential biomarkers of heart failure because they were in correlation with NT-pro-BNP and ejection fraction of the heart [41, 42].

On the other side, miRNA still has a small diagnostic potential when independent of troponin, and test conduction requires too much time [21]. Also there exist difficulties in practice when it comes to measuring absolute levels of miRNA, the lack of standardized protocols, and variations in test performance depending on the laboratory and heparin in the sample represents a significant inhibitor of reactions based on PCR method. Therefore it is crucial to improve methods and standardize protocols before final introduction of this biomarker in practice [43, 44]. However, it is considered that miRNA could represent an important cardiac biomarker in the near future (Table 2).

Table 2: Summary of original articles from the literature proving the significance of miRNA as cardiac biomarker.

Authors
Year
Study type
Number of patients
Statistical significance

Raitoharju et al. [32]
2011
Laboratory study
12 atherosclerotic plaques

Li et al. [31]
2011
Clinical study
104 patients with atherosclerosis obliterans
miR-21, miR-130a, miR-27b, let-7f, and miR-210 significantly increased

Cipollone et al. [33]
2011
Laboratory study
53 atherosclerotic plaques
miR-100, miR-127, miR-145, miR-133a, and miR-133b were more expressed in symptomatic versus asymptomatic plaques

Devaux et al. [36]
2015
Clinical study
224 patients with AMI
miR-208b, miR-499, and miR-320a were significantly higher in patients with AMI

Wang et al. [37]
2010
Clinical study
66 patients
miR-1, miR-133a, miR-499, and miR-208a in AMI

33 AMI, 33 non-AMI with chest pain and distress

Li et al. [38]
2013
Clinical study
67 patients with AMI
miR-1, miR-133a, miR-208b, and miR-499 in AMI < 0.001

Yao et al. [39]
2014
Clinical study
30 on-pump patients after coronary artery bypass surgery
miR-499, ;
miR-133a, ;
miR-133b,

4. The Significance of H-FABP as a Biomarker

Cytoplasmic FABP represent a family of transport proteins which allow the transport of fatty acids through the membranes. FABP show tissue specificity so there exist liver-type FABP (L-FABP), intestinal-type (I-FABP), brain-type FABP (B-FABP), and heart-type FABP (H-FABP). Expression of H-FABP is also specific for brain tissue while the coexpression of H-FABP and L-FABP is specific for kidney tissue [45]. These biomarkers have found their application in liver rejection and kidney viability assessment, in the diagnosis of inflammatory and ischemic intestinal diseases, in traumatic damage of brain tissue, and in the prevention of muscle damage in those who have intensive physical activity [45].

H-FABP represents a small cytosolic protein that functions as a carrier of long chain fatty acids in cardiomyocytes. It is present in high concentrations in myocardial tissue and is quickly released into the circulation after the damage of the myocardial tissue [46, 47].

When it comes to the patients with chest pain in primary medical care, it is considered that H-FABP is the most specific marker besides a highly sensitive troponin T (hs-cTnT) [48].

This molecule is recommended for the initial diagnosis of myocardial infarction as well as for the evaluation of minimal subclinical myocyte injury [1]. H-FABP has proved to be even more successful than cTnT in research when it comes to the diagnosis of myocardial damage in patients with chronic heart failure [1]. A high diagnostic sensitivity of H-FABP after myocardial damage has been proved, even 93.1% higher than CK-MB and cTnT [25]. Therefore it is considered that detection of positive H-FABP or cTnI indicates the possibility of the onset of myocardial damage [1].

H-FABP represents a highly accurate biomarker for the myocardial tissue damage in acute coronary syndromes and enables detection of minor myocardial tissue damage in the heart failure and unstable angina pectoris [45]. Elevated levels of H-FABP are present in circulation as soon as 2 to 3 hours after the damage and return to normal in 12 to 24 hours after the initial insult [25, 46].

The concentration of myoglobin is much higher in muscle tissue than in myocardial while it is reversed when it comes to H-FABP. Therefore it is considered that H-FABP is more specific biomarker for the assessment of myocardial tissue damage [45]. O’Donoghue et al. have shown that elevated levels of H-FABP are associated with an increased risk of cardiovascular events, onset of heart failure, and death during the first 10 months after the acute coronary syndrome. Moreover, this association is independent of other risk predictors (troponin I, creatinine clearance, patient’s history, etc.), age, and sex of the patient [46]. It has been proved that the prognostic significance of H-FABP is highly accurate and it can be successfully interpreted with troponin even in the patients with low and intermediate risk and in the patients with suspected acute coronary syndrome. Studies indicate that H-FABP can be used as a biomarker of myocardial ischemia even in the absence of evident necrosis [49]. H-FABP and TnT are detectable in venous blood of the patients with chronic heart failure with the ongoing myocardial damage. Some of the research show that H-FABP has a higher specificity [47]. H-FABP has shown to be a far more sensitive biomarker when compared to TnT within the first 6 hours after surviving acute heart damage; however, its specificity is reduced after 6 hours [50–53].

It is important to note that not only is H-FABP specific to myocardial tissue, but it is present in skeletal muscle in low concentrations. Most clinicians consider that damage of muscle tissue during the surgery cannot lead to such high levels of H-FABP. However, the damage of kidney tissue during the surgery may result in elevated levels of H-FABP [1]. Also, H-FABP can be elevated in the patients with kidney dysfunction [46].

Further extensive research is necessary in order to evaluate H-FABP as a biomarker of cardiovascular changes and long-term prognosis in the perioperative period (Table 3) [1].

Table 3: Summary of original articles from the literature proving the significance of H-FABP as cardiac biomarker.

Authors
Year
Study type
Number of patients
Statistical significance

Sari et al. [1]
2015
Clinical study
67 patients, 40 with diabetes

O’Donoghue et al. [46]
2006
Clinical study
2287 patients with acute coronary syndrome
Elevated in 332 patients (14.5%)

Niizeki et al. [47]
2007
Clinical study
126 patients with chronic heart failure

Willemsen et al. [48]
2015
Clinical study
202 patients with acute coronary syndrome
AUC 0.79 versus 0.80

Viswanathan et al. [49]
2010
Clinical study
1080 patients with suspected acute coronary syndrome

Ruzgar et al. [50]
2006
Clinical study
40 patients with suspected acute coronary syndrome

Mad et al. [51]
2007
Clinical study
22 patients with AMI

20 with unstable angina and 15 with noncardiac chest pain

Liao et al. [52]
2009
Clinical study
74 patients with AMI

Haltern et al. [53]
2010
Clinical study
97 with acute ischaemic chest pain

5. Significance of Proadrenomedullin as a Biomarker

Adrenomedullin (ADM) is a peptide which has rapid clearance from the circulation and a short half-life (22 minutes) and is not practical to be used as a routine biomarker. Midregional proadrenomedullin (MR-PAMP) is released in higher concentrations than ADM; it is inactive and has a longer half-life; therefore it represents a suitable substitute [12, 54–56].

Molecule PAMP is secreted from rat cardiomyocytes and there exist specific binding places for PAMP in heart tissue. One of its functions is that it is included in the control of coronary vasculatory tone. The level of PAMP is elevated in the patients with essential hypertension and congestive heart failure [14, 55].

Due to its stability and specificity, MR-PAMP is a significant biomarker for the prediction of heart damage since it basically represents a biomarker of endothelial dysfunction [54, 57]. The level of MR-PAMP is elevated in the patients with heart diseases like congenital heart failure, ischaemic heart disease, and atherosclerosis. It also represents a significant predictor of mortality in these individuals [57]. Smith et al. have shown that MR-PAMP, CRP, and NT-pro-BNP are good predictors of the onset of heart failure and that they are completely independent of the other biomarkers and risk factors [58]. The combination of MR-PAMP and Nt-pro-BNP is suggested for the mortality prediction [59, 60].

It has been examined whether a panel of biomarkers (PCT, MR-PAMP, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-ANP), each separately or using the Acute Physiology and Chronic Health Evaluation IV score, has a greater significance in the prediction of intrahospital mortality. It has been shown that the greatest significance in the first 6 to 18 hours after entering the ICU has MR-PAMP, even in the case when its significance has been compared to the Acute Physiology and Chronic Health Evaluation IV score in elective cardiosurgery [61].

Recently published BACH (Biomarkers in Acute Heart Failure) study pointed out that MR-PAMP has a much greater significance than BNP in the mortality prognosis within 90 days in patients with diagnosed acute heart failure [62, 63]. This supports the superiority of MR-PAMP compared to NT-pro-BNP and BNP in the prediction of mortality within 14 days [62–65].

A comparative analysis of 12 biomarkers showed that NT-pro-BNP, GDF-15, MR-PAMP, cystatin C, and MR-pro-ANP are the strongest predictors of cardiovascular complications in patients with stable angina pectoris, alone and in combination [66].

Elevated levels of MR-PAMP indicate the existence of coronary heart disease, heart failure, left ventricular failure, and complications in the septic patients [54]. Studies indicate the possibility of using MR-PAMP as a prognostic biomarker for subclinical and manifest cardiovascular diseases (Table 4) [67].

Table 4: Summary of original articles from the literature proving the significance of MR-PAMP as cardiac biomarker.

Authors
Year
Study type
Number of patients
Statistical significance

Eggers et al. [57]
2013
Cohort study
1797 patients over 70 years of age

Smith et al. [58]
2010
Cohort study
5187 individuals
Heart failure, ; atrial fibrillation,

Von Haehling et al. [59]
2007
Clinical study
525 patients with chronic heart failure

Von Haehling et al. [60]
2010
Clinical study
501 patients with chronic heart failure

6. Conclusion

Preoperative prediction of cardiovascular risk in patients who are preparing for non-cardiac surgery is essential. New protocols have confirmed that biomarkers have a significant role in that. The “multimarker strategy” is highly present in contemporary clinical practice because there are no independent biomarkers which would timely and accurately indicate the cardiomyocyte damage. The task of future studies is to find the “so-called” ideal biomarker, and studies which evaluate miRNA, H-FABP, and MR-PAMP give encouraging results.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

M. Sari, H. Kilic, O. Karakurt Ariturk, N. Yazihan, and R. Akdemir, “Diabetic patients have increased perioperative cardiac risk in heart-type fatty acid-binding protein-based assessment,” Medical Principles and Practice, vol. 24, no. 1, pp. 53–57, 2015.

Y. Cheng, R. Ji, J. Yue et al., “MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy?” The American Journal of Pathology, vol. 170, no. 6, pp. 1831–1840, 2007.

L. Goldman, “Cardiac risks and complications of noncardiac surgery,” Annals of Surgery, vol. 198, no. 6, pp. 780–791, 1983.

M. Licker, A. Schweizer, C. Ellenberger, J.-M. Tschopp, J. Diaper, and F. Clergue, “Perioperative medical management of patients with COPD,” The International Journal of Chronic Obstructive Pulmonary Disease, vol. 2, no. 4, pp. 493–515, 2007.

C. Schrimpf, H. Gillmann, B. Sahlmann et al., “Renal function interferes with copeotin in prediction of major adverse cardiac events in patients indergoing vascular surgery,” PLOS ONE, vol. 10, no. 4, Article ID e0123093, 2015.

D. H. Fitchett, S. G. Goodman, and A. Langer, “Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial,” Canadian Journal of Cardiology, vol. 24, no. 9, pp. 705–708, 2008.

T. H. Lee, E. R. Marcantonio, C. M. Mangione et al., “Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery,” Circulation, vol. 100, no. 10, pp. 1043–1049, 1999.

The Joint Task Force on Non-Cardiac Surgery: Cardiovascular Assessment and Management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA), “2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management,” European Journal of Anaesthesiology, vol. 31, pp. 517–573, 2014.

M. Kemp, J. Donovan, H. Higham, and J. Hooper, “Biochemical markers of myocardial injury,” British Journal of Anaesthesia, vol. 93, no. 1, pp. 63–73, 2004.

A. P. Kalogeropoulos, V. V. Georgiopoulou, and J. Butler, “Clinical adoption of prognostic biomarkers: The case for heart failure,” Progress in Cardiovascular Diseases, vol. 55, no. 1, pp. 3–13, 2012.

M. A. Hlatky, P. Greenland, D. K. Arnett et al., “Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association,” Circulation, vol. 119, no. 17, pp. 2408–2416, 2009.

N. Iqbal, B. Wentworth, R. Choudhary et al., “Cardiac biomarkers: new tools for heart failure management,” Cardiovascular Diagnosis and Therapy, vol. 2, no. 2, pp. 147–164, 2012.

G. Loncar, V. Tscholl, E. Tahirovic et al., “Should procalcitonin be measured routinely in acute decompensated heart failure?” Biomarkers in Medicine, vol. 9, no. 7, pp. 651–659, 2015.

G. Loncar, D. Omersa, N. Cvetinovic, A. Arandjelovic, and M. Lainscak, “Emerging biomarkers in heart failure and cardiac cachexia,” International Journal of Molecular Sciences, vol. 15, no. 12, pp. 23878–23896, 2014.

R. Marcun, A. Sustic, P. M. Brguljan et al., “Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease,” International Journal of Cardiology, vol. 161, no. 3, pp. 156–159, 2012.

M. Lainscak, S. von Haehling, and S. D. Anker, “Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers,” International Journal of Cardiology, vol. 132, no. 3, pp. 303–311, 2009.

W. Hochholzer, D. A. Morrow, and R. P. Giugliano, “Novel biomarkers in cardiovascular disease: update 2010,” American Heart Journal, vol. 160, no. 4, pp. 583–594, 2010.

B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005.

C. Zhang, “MicroRNAs: role in cardiovascular biology and disease,” Clinical Science, vol. 114, no. 11-12, pp. 699–706, 2008.

V. N. Kim, “Small RNAs: classification, biogenesis, and function,” Molecules and Cells, vol. 19, no. 1, pp. 1–15, 2005.

S. P. Romaine, M. Tomaszewski, G. Condorelli, and N. J. Samani, “MicroRNAs in cardiovascular disease: an introduction for clinicians,” Heart, vol. 101, no. 12, pp. 921–928, 2015.

T. Thum, “Facts and updates about cardiovascular non-coding RNAs in heart failure,” ESC Heart Failure, vol. 2, no. 3, pp. 108–111, 2015.

H.-W. Hwang and J. T. Mendell, “MicroRNAs in cell proliferation, cell death, and tumorigenesis,” British Journal of Cancer, vol. 94, no. 6, pp. 776–780, 2006.

M. Jovanovic and M. O. Hengartner, “miRNAs and apoptosis: RNAs to die for,” Oncogene, vol. 25, no. 46, pp. 6176–6187, 2006.

A. Gupta, P. Shukla, and V. D. Ashwalayan, “Clinical assessment of cardiovascular disorders by cardiac biomarkers,” International Journal of Pharmaceutical Sciences Review and Research, vol. 29, no. 1, pp. 87–94, 2014.

E. Raitoharju, N. Oksala, and T. Lehtimäki, “MicroRNAs in the atherosclerotic plaque,” Clinical Chemistry, vol. 59, no. 12, pp. 1708–1721, 2013.

A. A. Kondkar and K. K. Abu-Amero, “Utility of circulating MicroRNAs as clinical biomarkers for cardiovascular diseases,” BioMed Research International, vol. 2015, Article ID 821823, 10 pages, 2015.

F. Lovren, Y. Pan, A. Quan et al., “microRNA-145 targeted therapy reduces atherosclerosis,” Circulation, vol. 126, no. 11, pp. S81–S90, 2012.

I. Faraoni, F. R. Antonetti, J. Cardone, and E. Bonmassar, “miR-155 gene: a typical multifunctional microRNA,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1792, no. 6, pp. 497–505, 2009.

R. Ji, Y. Cheng, J. Yue et al., “MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation,” Circulation Research, vol. 100, no. 11, pp. 1579–1588, 2007.

T. Li, H. Cao, J. Zhuang et al., “Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans,” Clinica Chimica Acta, vol. 412, no. 1-2, pp. 66–70, 2011.

E. Raitoharju, L.-P. Lyytikäinen, M. Levula et al., “miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study,” Atherosclerosis, vol. 219, no. 1, pp. 211–217, 2011.

F. Cipollone, L. Felicioni, R. Sarzani et al., “A unique MicroRNA signature associated with plaque instability in humans,” Stroke, vol. 42, no. 9, pp. 2556–2563, 2011.

Y. Wei, M. Nazari-Jahantigh, P. Neth, C. Weber, and A. Schober, “ATVB in focus: MicroRNAs—from basic mechanisms to clinical application in cardiovascular medicine; MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 449–454, 2013.

E. Raitoharju, N. Oksala, and T. Lehtimäki, “microRNAs in the atherosclerotic plaque,” Clinical Chemistry, vol. 59, no. 12, pp. 1708–1721, 2013.

Y. Devaux, M. Mueller, P. Haaf et al., “Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain,” Journal of Internal Medicine, vol. 277, no. 2, pp. 260–271, 2015.

G.-K. Wang, J.-Q. Zhu, J.-T. Zhang et al., “Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans,” European Heart Journal, vol. 31, no. 6, pp. 659–666, 2010.

Y.-Q. Li, M.-F. Zhang, H.-Y. Wen et al., “Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction,” Clinics, vol. 68, no. 1, pp. 75–80, 2013.

Y. Yao, J. Du, X. Cao et al., “Plasma levels of microRNA-499 provide an early indication of perioperative myocardial infarction in coronary artery bypass graft patients,” PLoS ONE, vol. 9, no. 8, Article ID e104618, 2014.

S. Cardin, E. Guasch, X. Luo et al., “Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure,” Circulation: Arrhythmia and Electrophysiology, vol. 5, no. 5, pp. 1027–1035, 2012.

A. J. Tijsen, E. E. Creemers, P. D. Moerland et al., “MiR423-5p as a circulating biomarker for heart failure,” Circulation Research, vol. 106, no. 6, pp. 1035–1039, 2010.

S. K. Gupta, C. Bang, and T. Thum, “Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease,” Circulation: Cardiovascular Genetics, vol. 3, no. 5, pp. 484–488, 2010.

A. Zampetaki and M. Mayr, “Analytical challenges and technical limitations in assessing circulating MiRNAs,” Thrombosis and Haemostasis, vol. 108, no. 4, pp. 592–598, 2012.

T. S. Elton, M. Khan, and D. Terentyev, “microRNAs in cardiovascular disease,” F1000 Medicine Reports, vol. 3, article 10, 2011.

M. M. A. L. Pelsers, W. T. Hermens, and J. F. C. Glatz, “Fatty acid-binding proteins as plasma markers of tissue injury,” Clinica Chimica Acta, vol. 352, no. 1-2, pp. 15–35, 2005.

M. O'Donoghue, J. A. de Lemos, D. A. Morrow et al., “Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes,” Circulation, vol. 114, no. 6, pp. 550–557, 2006.

T. Niizeki, Y. Takeishi, T. Arimoto et al., “Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients,” Journal of Cardiac Failure, vol. 13, no. 2, pp. 120–127, 2007.

R. T. Willemsen, E. Van Severen, P. M. Vandervoort et al., “Heart-type fatty acid binding protein (H-FABP) in patients in an emergency department setting, suspected of acute coronary syndrome: optimal cut-off point, diagnostic value and future opportunities in primary care,” European Journal of General Practice, 2015.

K. Viswanathan, N. Kilcullen, C. Morrell et al., “Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative,” Journal of the American College of Cardiology, vol. 55, no. 23, pp. 2590–2598, 2010.

O. Ruzgar, A. K. Bilge, Z. Bugra et al., “The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band,” Heart and Vessels, vol. 21, no. 5, pp. 309–314, 2006.

P. Mad, H. Domanovits, C. Fazelnia et al., “Human heart-type fatty-acid-binding protein as a point-of-care test in the early diagnosis of acute myocardial infarction,” QJM, vol. 100, no. 4, pp. 203–210, 2007.

J. Liao, C. P.-Y. Chan, Y.-C. Cheung et al., “Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction,” International Journal of Cardiology, vol. 133, no. 3, pp. 420–423, 2009.

G. Haltern, S. Peiniger, A. Bufe, G. Reiss, H. Gülker, and T. Scheffold, “Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction,” The American Journal of Cardiology, vol. 105, no. 1, pp. 1–9, 2010.

G. W. D. Landman, P. R. van Dijk, I. Drion et al., “Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with Type 2 Diabetes (ZODIAC-30),” Diabetes Care, vol. 37, no. 3, pp. 839–845, 2014.

Z. Kaygısız, H. Özden, N. Erkasap et al., “Effects of proadrenomedullin N-terminal 20 peptide and calcitonin on isolated perfused rat hearts,” Anadolu Kardiyoloji Dergisi, vol. 9, no. 3, pp. 176–182, 2009.

T. Tsuruda, J. Kato, K. Kitamura et al., “Secretion of proadrenomedullin N-terminal 20 peptide from cultured neonatal rat cardiac cells,” Life Sciences, vol. 69, no. 2, pp. 239–245, 2001.

K. M. Eggers, P. Venge, B. Lindahl, and L. Lind, “Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community,” International Journal of Cardiology, vol. 168, no. 4, pp. 3537–3542, 2013.

J. G. Smith, C. Newton-Cheh, P. Almgren et al., “Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation,” Journal of the American College of Cardiology, vol. 56, no. 21, pp. 1712–1719, 2010.

S. Von Haehling, E. A. Jankowska, N. G. Morgenthaler et al., “Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 50, no. 20, pp. 1973–1980, 2007.

S. Von Haehling, G. S. Filippatos, J. Papassotiriou et al., “Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure,” European Journal of Heart Failure, vol. 12, no. 5, pp. 484–491, 2010.

A. Schoe, E. F. Schippers, J. Struck et al., “Postoperative pro-adrenomedullin levels predict mortality in thoracic surgery patients: comparison with Acute Physiology and Chronic Health Evaluation IV Score,” Critical Care Medicine, vol. 43, no. 2, pp. 373–381, 2015.

A. Maisel, C. Mueller, R. M. Nowak et al., “Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial,” Journal of the American College of Cardiology, vol. 58, no. 10, pp. 1057–1067, 2011.

A. Maisel, C. Mueller, R. Nowak et al., “Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial,” Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2062–2076, 2010.

W. F. Peacock, “Novel biomarkers in acute heart failure: MR-pro-adrenomedullin,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 10, pp. 1433–1435, 2014.

M. Potocki, R. Ziller, and C. Mueller, “Mid-Regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker,” Current Heart Failure Reports, vol. 9, no. 3, pp. 244–251, 2012.

R. B. Schnabel, A. Schulz, C. M. Messow et al., “Multiple marker approach to risk stratification in patients with stable coronary artery disease,” European Heart Journal, vol. 31, no. 24, pp. 3024–3031, 2010.

J. T. Neumann, S. Tzikas, A. Funke-Kaiser et al., “Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease,” Atherosclerosis, vol. 228, no. 2, pp. 451–459, 2013.

J. F. C. Glatz, M. van Bilsen, R. J. A. Paulussen, J. H. Veerkamp, G. J. van der Vusse, and R. S. Reneman, “Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox,” Biochimica et Biophysica Acta—Lipids and Lipid Metabolism, vol. 961, no. 1, pp. 148–152, 1988.

J. S. Ladue and F. Wroblewski, “The significance of the serum glutamic oxalacetic transaminase activity following acute myocardial infarction,” Circulation, vol. 11, no. 6, pp. 871–877, 1955.

W. E. C. Wacker, D. D. Ulmer, and B. L. Vallee, “Metalloenzymes and myocardial infarction—malic and lactic dehydrogenase activities and zinc concentrations in serum,” The New England Journal of Medicine, vol. 255, pp. 449–456, 1956.

R. J. Duma and A. L. Siegel, “Serum creatinine phosphokinase in acute myocardial infarction; diagnostic value,” Archives of Internal Medicine, vol. 115, pp. 443–451, 1965.

S. B. Rosalki, “Serum α-hydroxybutyrate dehydrogenase: a new test for myocardial infarction,” British Heart Journal, vol. 25, pp. 795–802, 1963.

D. J. Blomberg, W. D. Kimber, and M. D. Burke, “Creatine kinase isoenzymes: predictive value in the early diagnosis of acute myocardial infarction,” The American Journal of Medicine, vol. 59, no. 4, pp. 464–469, 1975.

M. el Allaf, J.-P. Chapelle, D. el Allaf et al., “Differentiating muscle damage from myocardial injury by means of the serum creatine kinase (CK) isoenzyme MB mass measurement/total CK activity ratio,” Clinical Chemistry, vol. 32, no. 2, pp. 291–295, 1986.

H. J. Saranchak and S. H. Bernstein, “A new diagnostic test for acute myocardial infarction. The detection of myoglobinuria by radioimmunodiffusion assay,” The Journal of the American Medical Association, vol. 228, no. 10, pp. 1251–1255, 1974.

J. Mair, F. Dienstl, and B. Pushendorf, “Cardiac troponin T in the diagnosis of myocardial injury,” Critical Reviews in Clinical Laboratory Sciences, vol. 29, no. 1, pp. 31–57, 1992.

B. Cummins, M. L. Auckland, and P. Cummins, “Cardiac-specific troponin-l radioimmunoassay in the diagnosis of acute myocardial infarction,” The American Heart Journal, vol. 113, no. 6, pp. 1333–1344, 1987.

T. Shimosawa, Y. Shibagaki, K. Ishibashi et al., “Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage,” Circulation, vol. 105, no. 1, pp. 106–111, 2002.